纳武利尤单抗对比多西他赛经治晚期NSCLC三年更新及肝转移亚组分析
CheckMate 017和057两项III期研究经≥3年随访更新:纳武利尤单抗对比多西他赛在经治晚期NSCLC中持续显示总生存获益,汇总人群3年OS率17%对8%。肝转移亚组纳武利尤单抗亦改善OS(HR 0.68,95%CI 0.50-0.91),安全性与总体一致。
要点
- 经治晚期NSCLC汇总人群3年OS率纳武利尤单抗17%对比多西他赛8%。
- 肝转移患者纳武利尤单抗对比多西他赛OS的HR为0.68(95%CI 0.50-0.91)。
- 纳武利尤单抗总体耐受良好,肝转移患者治疗相关肝脏不良事件略高(10%对6%)。
核心结论
- 经≥3年随访,纳武利尤单抗对比多西他赛在经治晚期NSCLC中持续显示总生存获益。
- 肝转移患者中纳武利尤单抗对比多西他赛同样显示总生存获益且耐受良好。
研究设计与样本
- CheckMate 017和057两项III期随机对照试验,患者按1:1随机接受纳武利尤单抗(3 mg/kg每2周)或多西他赛(75 mg/m2每3周)直至进展或停药。
- 两项研究主要终点均为总生存(OS),基线肝转移患者按治疗方式跨研究汇总进行亚组分析。
- 两项研究共854例随机患者,其中193例有基线肝转移。
- CheckMate 017和057最短随访时间分别为40.3个月。
主要发现
- 汇总鳞癌或非鳞NSCLC人群估计3年OS率纳武利尤单抗为17%(95%CI 14%-21%),多西他赛为8%(95%CI 6%-11%)。
- 肝转移患者中纳武利尤单抗对比多西他赛OS的HR为0.68(95%CI 0.50-0.91)。
- 总体汇总研究人群纳武利尤单抗对比多西他赛OS的HR为0.70(95%CI 0.61-0.81)。
- 纳武利尤单抗总体耐受良好,未发现新的安全性问题。
- 肝转移患者纳武利尤单抗治疗相关肝脏不良事件(主要为1-2级肝酶升高)发生率为10%,总体汇总人群为6%。
关键数值与推荐
- 纳武利尤单抗给药方案为3 mg/kg每2周,多西他赛为75 mg/m2每3周。
- 肝转移亚组纳武利尤单抗对比多西他赛OS的HR为0.68(95%CI 0.50-0.91)。
- 总体汇总人群纳武利尤单抗对比多西他赛OS的HR为0.70(95%CI 0.61-0.81)。
- 汇总人群3年OS率纳武利尤单抗17%(95%CI 14%-21%)对比多西他赛8%(95%CI 6%-11%)。
临床怎么用
- 经治晚期NSCLC患者可考虑纳武利尤单抗治疗,肝转移患者同样可获益。
- 肝转移患者接受纳武利尤单抗时需关注治疗相关肝脏不良事件,但多为1-2级肝酶升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a favorable safety profile with the anti-programmed death-1 antibody nivolumab versus docetaxel in patients with previously treated advanced squamous (CheckMate 017) and nonsquamous (CheckMate 057) NSCLC. We report results from ≥3 years' follow-up, including subgroup analyses of patients with liver metastases, who historically have poorer prognosis among patients with NSCLC. PATIENTS AND METHODS: Patients were randomized 1 : 1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m2 every 3 weeks) until progression or discontinuation. The primary end point of each study was OS. Patients with baseline liver metastases were pooled across studies by treatment for subgroup analyses. RESULTS: After 40.3 months' minimum follow-up in CheckMate 017 and 057, nivolumab continued to show an OS benefit versus docetaxel: estimated 3-year OS rates were 17% [95% confidence interval (CI), 14% to 21%] versus 8% (95% CI, 6% to 11%) in the pooled population with squamous or nonsquamous NSCLC. Nivolumab was generally well tolerated, with no new safety concerns identified. Of 854 randomized patients across both studies, 193 had baseline liver metastases. Nivolumab resulted in improved OS compared with docetaxel in patients with liver metastases (hazard ratio, 0.68; 95% CI, 0.50-0.91), consistent with findings from the overall pooled study population (hazard ratio, 0.70; 95% CI, 0.61-0.81). Rates of treatment-related hepatic adverse events (primarily grade 1-2 liver enzyme elevations) were slightly higher in nivolumab-treated patients with liver metastases (10%) than in the overall pooled population (6%). CONCLUSIONS: After 3 years' minimum follow-up, nivolumab continued to demonstrate an OS benefit versus docetaxel in patients with advanced NSCLC. Similarly, nivolumab demonstrated an OS benefit versus docetaxel in patients with liver metastases, and remained well tolerated. CLINICAL TRIAL REGISTRATION: CheckMate 017: NCT01642004; CheckMate 057: NCT01673867.
引用
- Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018. PMID: 29408986. doi:10.1093/annonc/mdy041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。